Inclusion body myositis pathomechanism and therapy;Újabb adatok az inclusiós testes myositis patomechanizmusáról és terápiájáról

Orvosi Hetilap

Volumn 149, Issue 30, 2008, Pages 1413-1418

  Váncsa, Andrea ^a,b   Dankó, Katalin ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Nagyerdei KRT 98   (Hungary)

Author keywords

Amyloid; Inclusion body myositis; MHC I CD8 complex

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETA1A INTERFERON; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PLACEBO; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TACROLIMUS; THYMOCYTE ANTIBODY; BIOLOGICAL MARKER; CD8 ANTIGEN; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

BREATHING MUSCLE; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DEGENERATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DYSPHAGIA; EARLY DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INCLUSION BODY MYOSITIS; INTERSTITIAL LUNG DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; PATHOGENESIS; QUALITY OF LIFE; REVIEW; BIOPSY; DRUG ANTAGONISM; ELECTROMYOGRAPHY; IMMUNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD8; BIOLOGICAL MARKERS; BIOPSY; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EARLY DIAGNOSIS; ELECTROMYOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MYOSITIS, INCLUSION BODY; PROGNOSIS;

EID: 50049100153     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2008.28070     Document Type: Review

References (18)

1. Dalakas, M. C.: Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology, 2006, 66, S33-S38.
2. Badrising, U. A., Maat-Schieman, M., van Duinen, S. G. és mtsai: Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology, 2000, 55, 1385-1387.
3. Yunis, E. J., Samaha, F. J.: Inclusion body myositis. Lab. Invest., 1971, 25, 240-248.
4. Engel, W. K., Askanas, V.: Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology, 2006, 66, S20-S29.
5. Fratta, P., Engel, W. K., McFcrrin, J. és mtsai: Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am. J. Pathol., 2005, 167, 517-526.
6. Engel W. K., Askanas, V.: Inclusion-body myositis. Clinical, diagnostic and pathologic aspects. Neurology, 2006, 66 (2 Suppl. 1), S20-29.
7. Oldfors, A., Moslemi, A. R., Jonasson, L. és mtsai: Mitochondrial abnormalities in inclusion-body myositis. Neurology, 2006, 66 (2 Suppl. 1), S49-S55.
8. Dalakas, M. C.: Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curt. Opin. Neurol., 2004, 17, 561-567.
9. Dalakas, M. C.: Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul. Disord., 2006, 16, 223-236.
10. Lotz, B. P., Engel, A. G., Nishino H. és mtsai: Inclusion body myositis. Observations in 40 patients. Brain, 1989, 112, 727-747.
11. Kula, R. W., Sawchak, J. A., Sher, J. H.: Inclusion body myositis. Curt. Opin. Rheumatol., 1989, 1, 460-467.
12. Finch, C. E.: A perspective on sporadic inclusion-body myositis: the role of aging and inflammatory processes. Neurology, 2006, 66 (2 Suppl. 1), S1-S6.
13. Griggs, R. C., Askanas, V., DiMauro, S. és mtsai: Inclusion body myositis and myopathies. Ann. Neurol., 1995, 38, 705-713.
14. Griggs, R. C.: The current status of treatment for inclusion-body myositis. Neurology, 2006, 66 (2 Suppl. 1), S30-S32.
15. Badrising, U. A., Maat-Schieman, M. L., Ferrari, M. D. és mtsai: Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann. Neurol., 2002, 51, 369-372.
16. Dalakas, M. C.: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol. Ther., 2004, 102, 177-193.
17. Walter, M. C., Lochmuller, H., Toepfer, M. és mtsai: High-dose inummoglobulin therapy in sporadic inclusion body myositis: a double-blind, place bo- controlled study. J. Neurol., 2000, 247, 22-28.
18. Barohn, R. J., Herbelin, L., Kissel, J. T. és mtsai: Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology, 2006, 66 (2 Suppl. 1), S123-S124.